Commercial risk will be a critical catalyst of progress – it’s complicated, but is it possible? We think so.
January 14, 2016
Even after being diagnosed with lung cancer, neurosurgeon Paul Kalanithi continued to practice medicine. But when a CT scan showed he had a new tumor, Kalanithi knew his days in the OR were ending.
The Advisory Board Company's Naomi Levinthal explains the implications of a CMS official's announcement that "the meaningful use program as it has existed will now be effectively over."
Print All Daily Briefing Article from
Ask our experts a question on any topic in health care by visiting our member portal, AskAdvisory.